Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days
Open Access
- 13 October 2005
- journal article
- Published by Wiley in Cancer Science
- Vol. 96 (10), 721-728
- https://doi.org/10.1111/j.1349-7006.2005.00109.x
Abstract
E7070 is a novel sulfonamide anticancer agent that disrupts the G1/S phase of the cell cycle. The objectives of this phase I study of E7070 were to estismate the maximal tolerated dose (MTD), to determine the recommended dose for phase II, and to clarify the pharmacokinetic profile of E7070 and its relation to polymorphisms of CYP2C9 (*2, *3) and CYP2C19 (*2, *3) in Japanese patients. Patients received 1–2‐h i.v. infusions of E7070 (400, 600, 700, 800 or 900 mg/m2) on day 1 of a 21‐day cycle. Twenty‐one patients received between one and eight cycles of E7070. The dose‐limiting toxicities (DLT) comprised leukopenia, neutropenia, thrombocytopenia, elevation of aspartate aminotransferase, colitis, and ileus. The mean area under the plasma concentration–time curve (AUC) for successive dose levels increased in a non‐dose‐proportional manner. Two patients were heterozygous for the CYP2C9 mutation. For CYP2C19, eight patients were wild type and the remainder had heterozygous (n = 8) or homozygous mutations (n = 5). Regarding the CYP2C19 genotype, the AUC of patients with mutant alleles were higher than those of patients with wild type at a dose of 600 mg/m2 or more. The severity of toxic effects, such as myelosuppression, seemed to depend on the AUC. No partial responses were observed. One patient treated at a dose of 700 mg/m2 experienced a maximum tumor volume reduction of 22.5%. The MTD was estimated to be 900 mg/m2. A dose of 800 mg/m2 is recommended for further phase II studies. The pharmacokinetic/pharmacodynamic properties of E7070 seemed to be influenced by CYP2C19 genotype. The observed safety profile and preliminary evidence of antitumor activity warrant further investigation of this drug in monotherapy or in combination chemotherapy. (Cancer Sci 2005; 96: 721 –728)This publication has 11 references indexed in Scilit:
- Pharmacokinetic Drug–Drug Interaction of the Novel Anticancer Agent E7070 and AcenocoumarolInvestigational New Drugs, 2004
- In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human bloodAnti-Cancer Drugs, 2003
- Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG)European Journal Of Cancer, 2003
- Phase I and Pharmacokinetic Study of E7070, a Novel Chloroindolyl Sulfonamide Cell-Cycle Inhibitor, Administered as a One-Hour Infusion Every Three Weeks in Patients With Advanced CancerJournal of Clinical Oncology, 2002
- Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-Early Clinical Studies Group (ECSG)Published by Elsevier BV ,2001
- Mechanisms of Action of the Novel Sulfonamide Anticancer Agent E7070 on Cell Cycle Progression in Human Non-Small Cell Lung Cancer CellsInvestigational New Drugs, 2001
- E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivoEuropean Journal Of Cancer, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Discovery of Novel Antitumor Sulfonamides Targeting G1 Phase of the Cell CycleJournal of Medicinal Chemistry, 1999
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999